Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

The FDA has started a priority review of MSD's Keytruda as neoadjuvant and adjuvant treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), with a decision due by 23rd June.

HPV driven cancers, including HPV+ HNSCC, are characterized by defects in the DDR pathway, making them potentially susceptible to WEE1 inhibition. HPV+ cancers are those where the underlying cause ...

The randomised trial aims to evaluate the bifunctional antibody in conjunction with pembrolizumab, an existing immunotherapy for HNSCC, to investigate the improvements in subject outcomes.

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC). The research identified enolase 2 (ENO2), a ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).The research identified enolase 2 (ENO2), a ...

Significant clinical responses were observed in patients with head and neck squamous cell carcinoma (HNSCC). PYX-201 achieved ... or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC ...